First, IL-18BP itself is not the cause of the poor outcomes for IPF; although IL-18BP itself has anti-fibrotic and/or anti-inflammatory activity, its increased expression simply reflects increased expression of IL-18, which can promote lung fibrosis. The gene discussed is IL18; the disease is pulmonary fibrosis.